Labospace
Private Company
Funding information not available
Overview
Founded in 2015 and headquartered in Milan, Italy, Labospace operates as a service provider in the Diagnostics and Digital Health sectors. Its core business is offering high-throughput, multiplexed biomarker assay services using technologies such as Luminex, alongside distributing IVD reagents and educational tools. The company is ISO-certified, targets a diverse client base from pharma to academia, and emphasizes flexible, cost-effective laboratory solutions.
Technology Platform
Utilizes high-throughput platforms including Luminex/multiplex assays, Next-Generation Sequencing (NGS), Flow Cytometry (FACS), and Immunohistochemistry (IHC) to provide customized biomarker assay and analytical services.
Opportunities
Risk Factors
Competitive Landscape
Labospace competes in the fragmented contract research and lab services market, facing competition from large global CROs (e.g., LabCorp, IQVIA), specialized central labs, and numerous small local service providers. Its differentiation lies in platform flexibility, customization, and a focus on the Italian/European market. In educational products, it competes with other suppliers of classroom molecular biology equipment.